SAN JOSE, Calif., Nov. 26, 2019 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on harnessing the body's immune system in the fight against cancer,
today announced the addition of Genesis Research, LLC to the
ongoing Cchek™ prostate cancer detection study.
Genesis Research, LLC the research arm of Genesis Healthcare
Partners, based in San Diego, CA,
joins a large and growing team of collaborators advancing Anixa's
Cchek™ artificial intelligence driven liquid biopsy technology
toward commercialization. Genesis Research will provide
patient samples in support of clinical validation of Anixa's Cchek™
Prostate Cancer Confirmation test.
Study enrollment will be led by Genesis Research's Medical
Director, Dr. Paul Dato. Dr.
Dato commented, "This is an exciting opportunity for research
personnel at Genesis Healthcare Partners to collaborate with Anixa
and explore the potential of immune cells to detect the presence of
Prostate Cancer."
Dr. Franklin Gaylis, Chief
Scientific Officer at Genesis Healthcare Partners, has endorsed the
collaboration between the two organizations and commented, "Genesis
Healthcare Partners has an active research program focused on the
early detection of Prostate Cancer. Our collaboration with
Anixa provides a great opportunity to explore the potential for
developing a liquid biopsy for detecting Prostate Cancer."
Amit Kumar, Ph.D., Chief
Executive Officer of Anixa stated, "We are pleased to have Genesis
Research join our expanding group of Cchek™ collaboration
partners. Our team of collaborators have been and continue to
be instrumental in the development of our early cancer detection
technology. We look forward to Genesis Research's
participation as we prepare for commercial launch of the Cchek™
Prostate Cancer Confirmation test in the coming weeks."
About Cchek™
Cchek™ is an early cancer detection
technology, that measures a patient's immunological response to a
malignancy by analyzing immune system cells in peripheral blood.
The goal is to utilize the technology to determine a
patient's cancer status from a simple blood draw, eliminating the
need for a biopsy, which can be an expensive, painful and invasive
procedure. Further, conventional methods using current cancer
screening tests often lack accuracy and reliability. Anixa's
orthogonal approach using flow cytometry coupled with artificial
intelligence provides an alternative method that offers improved
affordability, efficacy and efficiency. To date, Anixa has
successfully used Cchek™ to detect the presence of 20 different
cancers including lung, colon, breast and prostate. The
robust cancer detection performance of Cchek™ makes it a platform
from which multiple cancer diagnostic tests may be developed.
The first such test, a prostate cancer confirmation test, is slated
for commercial launch by the end of 2019.
Genesis Research, LLC
Genesis Research is the wholly
owned research subsidiary of Genesis Healthcare Partners,
San Diego's largest premier
multi-specialty independent private physician practice, dedicated
to the diagnosis and treatment of urologic conditions, digestive
health issues and many cancers. With 15 offices located
throughout San Diego County,
Genesis Healthcare Partners' team of medical professionals provides
access to cutting-edge technology and minimally invasive
treatments. Additional information is available at
www.mygenesishealth.com.
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company focused on harnessing the
body's immune system in the fight against cancer. Anixa's
therapeutic portfolio includes a cancer vaccine technology focused
on the immunization against α-Lactalbumin to prevent triple
negative breast cancer (TNBC), as well as a cancer immunotherapy
program which uses a novel type of CAR-T, known as chimeric
endocrine receptor T-cell (CER-T) technology. The company's
diagnostic portfolio consists of Cchek™, a liquid biopsy technology
for early detection of solid tumors based on the body's immune
response to the presence of a malignancy. Anixa continually
examines emerging technologies in complementary fields for further
development and commercialization. Additional information is
available at www.anixa.com.
Forward-Looking Statements: Statements
that are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You
are cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Tiberend Strategic Advisors, Inc.
Miriam Miller (Investors)
mmiller@tiberend.com
212-375-2694
Johanna Bennett (Media)
jbennett@tiberend.com
212-375-2686
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-announces-genesis-research-to-join-cchek-prostate-cancer-study-300964956.html
SOURCE Anixa Biosciences, Inc.